Key Highlights:
- Kashiv BioSciences entered an exclusive licensing and supply agreement with Intas Pharmaceuticals for the commercialization of a complex peptide product across Europe, the UK, and India.
- Under the agreement, Kashiv will oversee regulatory registration, manufacturing, and supply of the product, while Accord Healthcare, a subsidiary of Intas, will lead commercialization and distribution in Europe and the UK, with Intas responsible for the Indian market.
- The collaboration is expected to expand Kashiv’s commercial footprint across key international markets while strengthening Intas’ specialty portfolio and improving access to high-quality peptide-based therapies.
Implications:
This partnership accelerates peptide therapy access in high-growth markets, challenging incumbents like Sun Pharma in India’s $500M+ peptide segment while leveraging Intas’ Accord network for 20-25% EU share gains.
Intas gains differentiated complex peptides amid biosimilar competition, potentially lifting specialty revenues 15% as complex generics face pricing pressures.
Overall, it signals PE consolidation in peptide CDMO space, spurring India-Europe supply chain integration for injectables.
Source: Businesswire
